Revenue
2020
2021
2022
2023
2024
2025
Tango Therapeutics, Inc. (TNGX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M | $7.7M |
| Research & development | $132.2M | $143.9M | $115.2M | $105.9M | $77.6M | $50.0M |
| Operating expenses | $173.7M | $187.7M | $150.7M | $135.9M | $95.2M | $59.9M |
| Operating income | −$111.3M | −$145.6M | −$114.2M | −$111.1M | −$58.2M | −$52.2M |
| Net income | −$101.6M | −$130.3M | −$101.7M | −$108.2M | −$58.2M | −$52.0M |
| Basic EPSper diluted share | -$0.87 | -$1.19 | -$1.08 | -$1.23 | -$0.94 | -$1.63 |
| Diluted EPSper diluted share | -$0.87 | -$1.19 | -$1.08 | -$1.23 | -$0.94 | -$1.63 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 · 10b5-1 | Crystal AdamPresident, R&D | SellCommon Stock | 20.9K | $23.06 | $481.0K | 115.7K |
| Jun 1, 2026Form 4 · 10b5-1 | Crystal AdamPresident, R&D | SellCommon Stock | 6.1K | $22.25 | $136.6K | 136.6K |
| May 1, 2026Form 4 · 10b5-1 | Crystal AdamPresident, R&D | SellCommon Stock | 1.1K | $22.00 | $24.2K | 115.7K |
| May 1, 2026Form 4 · 10b5-1 | Crystal AdamPresident, R&D | SellCommon Stock | 25.9K | $21.19 | $548.8K | 116.8K |
| Apr 15, 2026Form 4 · 10b5-1 | Crystal AdamPresident, R&D | SellCommon Stock | 38.5K | $25.00 | $961.5K | 112.6K |